CTS Corporation raised its full-year 2026 guidance following second-quarter results that included record adjusted gross margin and a 30% jump in adjusted earnings per share. Revenue rose 7% year over year to $144.8 million, driven by a 45% surge in medical sales and a 16% increase in industrial sales, while transportation revenue slipped 2%. Adjusted gross margin reached a record 41.5%, and adjusted diluted EPS climbed to $0.74. The company now expects 2026 sales of $565 million to $585 million and adjusted diluted EPS of $2.55 to $2.70, supported by continued diversified-market growth despite uncertainty in transportation, tariffs, and input costs.
CTS CorporationCTS raised 2026 guidance after record margins and 30% EPS growth.
CTS Co., Ltd.